Justice's Death Has Implications For Patent, Biosimilars Cases
This article was originally published in Scrip
Executive Summary
With the Feb. 13 death of US Supreme Court Justice Antonin Scalia, cases affecting the biopharmaceutical industry currently pending before the court or those expected to reach it in the next year or two may now have different outcomes than they otherwise would have with him weighing in on those decisions.